Daniel Tassé

Biography

Daniel Tassé is a CEO and Chairman of Alcresta Therapeutics. Prior to the acquisition of Ikaria by Mallinckrodt in April 2015, Mr. Tassé was President and Chief Executive Officer and Chairman of the Board of Ikaria and served as our interim Chief Executive Officer and President from February 2014 to June 2014. Previously, Mr. Tassé was the General Manager of the Pharmaceuticals and Technologies Business Unit of Baxter International, Inc. a global diversified healthcare company and Vice President and Regional Director for Australasia at GlaxoSmithKline. Mr. Tassé currently serves as a Director of Indivior PLC, a London Stock Exchange publicly traded company, and serves on its Audit Committee and Science & Policy Committee. Mr. Tassé also serves as a Director of Regenxbio, a Nasdaq listed company, and serves on its Compensation Committee. Mr. Tassé is also a Director or BioQ Pharma, a private company. For many years, until June 2015, Mr. Tassé was a member of the Healthcare Leadership Council, a member of the Health Section Governing Board of the Biotechnology Industry Organization and a member of the Board of Directors of the Pharmaceutical Research and Manufacturers Association of America. Mr. Tassé received a B.Sc. in biochemistry form the University of Montreal.

Research Interest

Medical Devices